217 results about "Brain traumas" patented technology

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses a rapid detection method for traumatic brain injury by fusing genetic engineering and quantum dots, and relates to the technical field of traumatic brain injury detection. The method comprises the following steps: acquiring a suspected patient biological sample, extracting biomolecule components, and comparing the biomolecule components with a healthy population biomolecule database to obtain related differential expression molecules. A specifically recognizable recombinant antibody is constructed by genetic engineering, and is connected with a quantum dot through a coupling reaction to prepare a detection probe. The probe and a biological sample are mixed and reacted, and the intensity of a fluorescence signal generated by combination is collected by a fluorescence detection device. A standardized signal value is obtained through signal processing algorithm noise reduction and feature extraction, and a preliminary detection result is determined by combining a bioinformatics database evaluation sample. And finally, according to the differential expression molecule, the standardized signal value and the preliminary result, analyzing a data change trend in a preset time window by using a multivariable statistical model, and generating a diagnosis report. According to the method, various technologies are fused, and a new path is provided for traumatic brain injury detection.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

The invention belongs to the technical field of medical instruments, and discloses a surgical instrument for building a traumatic brain injury mouse model.The surgical instrument comprises a tube blade, a limiter, a holding piece and a vacuum device, the tube blade is used for rotationally cutting into brain tissue of a mouse, the limiter is movably installed on the tube blade in the axial direction of the tube blade, and the vacuum device is arranged on the holding piece; the limiting device is used for abutting against the skull of the mouse, the holding piece is provided with an airflow channel, one end of the holding piece is connected with the pipe blade, one end of the airflow channel is communicated with the pipe blade, and the vacuum device is connected to the other end of the holding piece and connected with the other end of the airflow channel. According to the surgical instrument for building the traumatic brain injury mouse model, the problems that an injury area is uncontrollable and a focus area is difficult to quantify and unify in the current traumatic brain injury mouse model building process can be solved, so that the success rate and efficiency of model building are improved to the maximum extent.

A system for evaluating cognitive function is disclosed herein. In some embodiments, the system includes a computing device with a processor; and a visual display device. The computing device is operatively coupled to said visual display device, said computing device being programmed to generate and display a cognitive test on said visual display device for assessing a mental ability of said patient, said cognitive test comprising a plurality of different images for said patient to identify, said cognitive test assessing the mental ability of said patient that is suspected of having sustained a traumatic brain injury (TBI). Also, in some embodiments, the system is in a form of a telemedicine system that includes a local control system disposed at a first location and a central control system disposed at a remote site.

This paper presents a medical device for treating traumatic brain injury and cerebral thrombosis through electroacupuncture. The device includes a 6-DOF (degree of freedom) mechanical arm, a multifunctional tool tip, an MRI helmet suitable for acupuncture, and magnetic resonance imaging (MRI). The acupuncture robot can insert needles and automatically manipulate specific needles by rotating or vibrating them within a specific frequency range, and can enhance the effect by applying electrical stimulation.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

The present invention relates to compounds, compositions and methods for deinhibiting a RE1 silencing transcription factor (REST) target gene. In particular, disclosed is a peptide having the sequences TEDLEPPEPPLPKEN (SEQ ID NO: 1) and EDLEPPEPPLPK (SEQ ID NO: 15) or a reverse sequence (reverse inversion, RI) consisting of D-amino acids nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), for use in the inhibition of REST activity. The peptides can be used for treating, preventing or alleviating diseases such as traumatic brain injury, epilepsy, dementia, Huntington's disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer, diabetes and peripheral nerve injury.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The disclosure relates to compositions including STING inhibitors. Methods of treating subjects with a traumatic brain injury by administering STING inhibitors are also included.

The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone / sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone / sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

Methods for treating injuries to the central nervous system with a cilia activator are provided. The injury may be a traumatic brain injury (TBI). Related pharmaceutical compositions are provided.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

The head protection helmet comprises a protection helmet structure, U-shaped component force ropes are fixedly installed at the positions, close to the edges of the two sides, of the lower end opening of the protection helmet structure, and anti-disengaging elastic bands are connected to the middles of the surfaces of the two U-shaped component force ropes. A buffering protection structure is fixedly installed on the inner side surface of the protection helmet structure in a nested mode, D breathable mesh cloth is fixedly installed on the inner side surface of the buffering protection structure, the protection helmet structure comprises alloy plastic and an outer-layer soft package, and the outer surface of the alloy plastic is fixedly wrapped with the outer-layer soft package. According to the head protection helmet for the patient with the craniocerebral injury, the head protection helmet for the patient with the craniocerebral injury can be adaptively inflated according to the size of the head of the patient so that the head protection helmet can be fixedly worn in an attached mode, and therefore the head protection helmet is more stable to wear; and the patient can be further protected through two air bag buffer layers, namely the tensioning air bag and the protection air bag.

Disclosed are therapeutic methods comprising the delivery of particular substituted pyridine based compounds for lowering intracranial pressure (ICP) and / or lowering neurogenic inflammation in treating substance P mediated pathways in the brain such as, but not limited to concussion, post-concussive (or post-concussion) syndrome (PCS), traumatic brain injury (TBI) and stroke.

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

Provided are systems, methods, and devices for providing mediation of a traumatic brain injury. Systems may include an interface, processing devices, and a controller. The interface is configured to obtain measurements from a brain of a user with a traumatic brain injury. A first processing device is configured to generate multiple brain state parameters characterizing one or more features of a brain state of the user. A second processing device is configured to generate models of the brain of the user based on the plurality of brain state parameters and the plurality of measurements, and determine, using the models and training data comprising one or more mediation data points, a mediation procedure for reducing one or more symptoms of the traumatic brain injury. The mediation procedure is provided to one or more entities, and one or more control signals are generated by the controller based on the mediation procedure.

Disclosed are compounds, compositions, and methods for inhibiting tyrosine-mediated DNA repair in a neuroprotective manner and / or activating transcription and / or protein synthesis. Compositions include a resveratrol, such as cis-resveratrol, or a compound of Formula I or Formula II. Compounds of Formula I and Formula II have the following structureswhere the variables, e.g., Y1, Y2, Y3, R1, R2, R3 the A-ring, and W are defined herein. Said compound and compositions may be utilized in treating aging and age-associated neurocognitive and metabolic disorders including various types of cancer. In particular, compositions disclosed herein are neuroprotective against tyrosine / phenylalanine or their metabolites-mediated neurodegeneration and neurocognitive disorders. The disclosure also includes combination pharmaceutical compositions and methods of treatment in which cis-resveratrol, a compound of Formula I, a compound of Formula II, or a pharmaceutically acceptable salt thereof is used in combination with a GLP-1 receptor agonist for treating a traumatic brain injury or a neurodegenerative disorder.

This invention relates to pharmaceutical compositions, including compositions adapted for intranasal administration, comprising an active ingredient, including dexmedetomidine, pomalidomide, a selective phosphodiesterase type 4 inhibitor such as roflumilast, or combinations thereof, useful in the treatment of traumatic brain injury (TBI), including to prevent or reduce the neurological sequalae of TBI.

Disclosed is a method of method of treating a disease in a subject, comprising the step of administering to a subject in need thereof a solution of a solid pharmaceutical composition containing a compound of formula (I) and / or formula (II), wherein the disease is selected from the group consisting of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, witha compound having formula (I) being:and a compound having the formula (II) being:

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The present application relates to the technical field of intelligent analysis and injury identification of traffic accidents, and discloses a pedestrian-oriented repetitive brain injury risk identification method, which comprises the following steps: constructing an accident database containing human-vehicle and human-ground secondary collision; simulating and restoring the accident scene and extracting head acceleration time history and brain tissue maximum principal strain; performing time-frequency decomposition by wavelet packet transform and calculating wavelet packet energy; linearly weighting and fusing the brain tissue strain of the two collisions by taking the energy proportion as a weighting coefficient to obtain a multi-modal fusion index; constructing a damage probability model based on Weibull distribution, completing parameter maximum likelihood estimation through Bernoulli likelihood function, establishing a damage risk curve, verifying and optimizing the damage risk curve, and finally forming a practical brain injury risk identification curve. The present application comprehensively uses time domain, frequency domain and strain information, quantifies the cumulative damage effect of repetitive collision, effectively improves the comprehensiveness and accuracy of pedestrian brain injury evaluation, and is suitable for vehicle safety design and traffic accident injury identification.

The application discloses a kind of bioengineered apoptotic bodies based on apoptotic body membrane protein and liposome and preparation method and application thereof.The bioengineered apoptotic bodies are formed by the chimerization of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5.The bioengineered apoptotic bodies simulating the natural apoptosis process of mesenchymal stem cells can promote the polarization of microglial cells to M2 type, release anti-inflammatory factors and neurotrophic factors, promote the proliferation of neurons, improve the antioxidant capacity of cells, improve the nervous motor function, relieve brain edema, and thus effectively treat traumatic brain injury.